If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Please cite this paper as: McLintock C, McCowan L, North R. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG 2009; DOI: 10.1111/j.1471-0528.2009.02299.x. Objective 

To determine maternal and fetal outcomes in women with mechanical heart valves managed with therapeutic dose enoxaparin during pregnancy. Design 

Retrospective audit. Setting 

Hospital-based high-risk antenatal clinics. Population 

Pregnant women with mechanical heart valves attending high-risk antenatal clinics, treated with enoxaparin (1 mg/kg twice daily) during pregnancy. Methods 

Women with mechanical heart valves treated with enoxaparin at any stage during pregnancy (1997–2008) identified using a database of women with mechanical heart valves attending the high-risk clinics and a prospective database of women prescribed enoxaparin for any indication during pregnancy. Main outcome measures 

Maternal outcomes included thromboembolic and haemorrhagic complications. Pregnancy and fetal outcomes included miscarriage, stillbirth, baby death and live birth, small-for-gestational-age infants, warfarin embryopathy and warfarin-related fetal loss. Results 

Thirty-one women underwent 47 pregnancies. In 34 pregnancies (72.3%), anticoagulation was with predominantly enoxaparin and 13 (27.7%) pregnancies women received mainly warfarin, with enoxaparin given in the first trimester and/or peri-delivery. Seven (14.9%) thrombotic complications occurred, of which five (10.6%) were associated with enoxaparin treatment. Non-compliance or sub-therapeutic anti-Xa levels contributed in each case. Antenatal and postpartum haemorrhagic complications occurred in eight (17%) and 15 (32%) pregnancies respectively. Of 35 pregnancies continuing after 20 weeks’ gestation, 96% (22/23) of women taking predominantly enoxaparin had a surviving infant compared with 75% (9/12) in women taking primarily warfarin. Four perinatal deaths occurred, three attributable to warfarin. Conclusions 

Compliance with therapeutic dose enoxaparin and aspirin during pregnancy in women with mechanical heart valves is associated with a low risk of valve thrombosis and good fetal outcomes, but close monitoring is essential.

Keywords: Anticoagulation; enoxaparin; mechanical heart valves; pregnancy; thrombosis

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1471-0528.2009.02299.x

Affiliations: 1: National Women’s Health, Auckland City Hospital, Auckland, New Zealand 2: Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand 3: Discipline of Obstetrics and Gynaecology, School of Pediatrics and Reproductive Health, University of Adelaide, Adelaide, SA, Australia

Publication date: November 1, 2009

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more